[Combined antibacterial therapy of infectious complications in oncological patients].
Rational antibacterial therapy of infections in oncological patients in relation to the polyetiological nature of the infections and polyresistance of their causative agents contemplates the use of drug combinations. The necessity of long-term antibacterial therapy in many oncological patients also predisposes to it. The choice of drugs for every patient should stem from bacteriological findings: isolation of the pathogen, its identification and assay of its antibiotic sensitivity. When isolation of the causative agent is not possible or could not be done immediately the drug should be chosen according to the general data on the etiological structure of infectious complications in the particular department and particular pathological process as well as antibiotic sensitivity of the bacteria isolated under such conditions.
Smolianskaia
A Z
AZ
D000583:Amikacin / Q000008:administration & dosage*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000209:etiology; D002228:Carbenicillin / Q000008:administration & dosage*; D002437:Cefazolin / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects; D009369:Neoplasms / Q000150:complications* / Q000276:immunology; D009894:Opportunistic Infections / Q000188:drug therapy* / Q000209:etiology
D000583:Amikacin; D002228:Carbenicillin; D002437:Cefazolin
Kombinirovannaia antibakteria'lnaia terapiia infektsionnykh oslozhneniĭ u onkologicheskikh bo'lnykh.